Literature DB >> 19590507

Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats.

Hideo Shimizu1, Hironori Nakagami, Mariana Kiomy Osako, Futoshi Nakagami, Yasuo Kunugiza, Tetsuya Tomita, Hideki Yoshikawa, Hiromi Rakugi, Toshio Ogihara, Ryuichi Morishita.   

Abstract

A recent analysis of clinical studies suggests that angiotensin-converting enzyme (ACE) inhibitors might reduce bone fractures. In this study, we examined whether an ACE inhibitor might attenuate osteoporosis in a hypertensive rat model. In spontaneous hypertensive rats (SHRs), estrogen deficiency induced by ovariectomy (OVX) resulted in a significant increase in osteoclast activation as assessed by the tartrate-resistant acid phosphatase (TRAP) activity in the tibia, accompanied by a significant decrease in bone density evaluated by dual-energy X-ray absorptiometry and an increase in urinary deoxypyridinoline. Treatment with an ACE inhibitor, imidapril, attenuated OVX-induced decrease in bone density and increase in TRAP activity and urinary deoxypyridinoline. As ACE inhibitors possess the effects of blockade of the renin-angiotensin system (RAS) and activation of the bradykinin-nitric oxide pathway, we examined the contribution of both pathways in an OVX-induced osteoporosis model. Administration of nitro-L-arginine methylester (L-NAME) did not alter TRAP activity, urinary deoxypyridinoline or bone density, whereas the administration of a subpressor dose of angiotensin II accelerated the increase in TRAP activity in the tibia, accompanied by a significant decrease in bone density and an increase in urinary deoxypyridinoline. Thus, ACE inhibitors prevented osteoporosis, probably because of the inhibition of RAS, but not of nitric oxide. Overall, ACE inhibitors attenuated osteoporosis in a hypertensive rat model through the blockade of RAS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19590507     DOI: 10.1038/hr.2009.99

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  22 in total

1.  Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome.

Authors:  Harikiran Nistala; Sui Lee-Arteaga; Luca Carta; Jason R Cook; Silvia Smaldone; Gabriella Siciliano; Aaron N Rifkin; Harry C Dietz; Daniel B Rifkin; Francesco Ramirez
Journal:  Hum Mol Genet       Date:  2010-09-24       Impact factor: 6.150

2.  ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men.

Authors:  Timothy Kwok; Jason Leung; Elizabeth Barrett-Connor
Journal:  Age Ageing       Date:  2017-01-10       Impact factor: 10.668

Review 3.  Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis.

Authors:  Mahua Ghosh; Sumit R Majumdar
Journal:  Endocrine       Date:  2014-02-07       Impact factor: 3.633

4.  Renin inhibitor aliskiren exerts beneficial effect on trabecular bone by regulating skeletal renin-angiotensin system and kallikrein-kinin system in ovariectomized mice.

Authors:  Y Zhang; L Wang; Y Song; X Zhao; M S Wong; W Zhang
Journal:  Osteoporos Int       Date:  2015-10-06       Impact factor: 4.507

5.  Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men?

Authors:  T Kwok; J Leung; Y F Zhang; D Bauer; K E Ensrud; E Barrett-Connor; P C Leung
Journal:  Osteoporos Int       Date:  2011-11-12       Impact factor: 4.507

6.  Continuous infusion of angiotensin II modulates hypertrophic differentiation and apoptosis of chondrocytes in cartilage formation in a fracture model mouse.

Authors:  Hirohisa Kawahata; Daisuke Sotobayashi; Motokuni Aoki; Hideo Shimizu; Hironori Nakagami; Toshio Ogihara; Ryuichi Morishita
Journal:  Hypertens Res       Date:  2015-02-19       Impact factor: 3.872

7.  Association of Circulating Renin and Aldosterone With Osteocalcin and Bone Mineral Density in African Ancestry Families.

Authors:  Allison L Kuipers; Candace M Kammerer; J Howard Pratt; Clareann H Bunker; Victor W Wheeler; Alan L Patrick; Joseph M Zmuda
Journal:  Hypertension       Date:  2016-03-14       Impact factor: 10.190

Review 8.  Heart failure as a risk factor for osteoporosis and fractures.

Authors:  Aloice O Aluoch; Ryan Jessee; Hani Habal; Melinda Garcia-Rosell; Rehan Shah; Guy Reed; Laura Carbone
Journal:  Curr Osteoporos Rep       Date:  2012-12       Impact factor: 5.096

9.  Improved trabecular bone structure of 20-month-old male spontaneously hypertensive rats.

Authors:  Tzu-Cheng Lee; Andrew J Burghardt; Wei Yao; Nancy E Lane; Sharmila Majumdar; Grant T Gullberg; Youngho Seo
Journal:  Calcif Tissue Int       Date:  2014-08-09       Impact factor: 4.333

10.  Effects of angiotensin-converting enzyme inhibitor, captopril, on bone of mice with streptozotocin-induced type 1 diabetes.

Authors:  Teng-Yue Diao; Hai Pan; Sa-Sa Gu; Xi Chen; Fang-Yi Zhang; Man-Sau Wong; Yan Zhang
Journal:  J Bone Miner Metab       Date:  2013-08-10       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.